These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33563642)

  • 1. Adjuvant brachytherapy for FIGO stage I serous or clear cell endometrial cancer.
    Jeans EB; Breen WG; Mullikin TC; Looker BA; Mariani A; Keeney GL; Haddock MG; Petersen IA
    Int J Gynecol Cancer; 2021 Jun; 31(6):859-867. PubMed ID: 33563642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
    Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
    Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.
    Murphy KT; Rotmensch J; Yamada SD; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1272-6. PubMed ID: 12654437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer.
    Barney BM; Petersen IA; Mariani A; Dowdy SC; Bakkum-Gamez JN; Haddock MG
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):109-15. PubMed ID: 22543202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
    Young MR; Higgins SA; Ratner E; Yu JB; Mani S; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Damast S
    Int J Gynecol Cancer; 2015 Mar; 25(3):431-9. PubMed ID: 25621409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer.
    Dunn EF; Geye H; Platta CS; Gondi V; Rose S; Bradley KA; Anderson BM
    Gynecol Oncol; 2014 Jun; 133(3):494-8. PubMed ID: 24657301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.
    Turner BC; Knisely JP; Kacinski BM; Haffty BG; Gumbs AA; Roberts KB; Frank AH; Peschel RE; Rutherford TJ; Edraki B; Kohorn EI; Chambers SK; Schwartz PE; Wilson LD
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):77-84. PubMed ID: 9422561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.
    Randall ME; Filiaci V; McMeekin DS; von Gruenigen V; Huang H; Yashar CM; Mannel RS; Kim JW; Salani R; DiSilvestro PA; Burke JJ; Rutherford T; Spirtos NM; Terada K; Anderson PR; Brewster WR; Small W; Aghajanian CA; Miller DS
    J Clin Oncol; 2019 Jul; 37(21):1810-1818. PubMed ID: 30995174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma.
    Mundt AJ; Murphy KT; Rotmensch J; Waggoner SE; Yamada SD; Connell PP
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1154-60. PubMed ID: 11483324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
    Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
    Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
    Alektiar KM; Venkatraman E; Chi DS; Barakat RR
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation.
    Jolly S; Vargas CE; Kumar T; Weiner SA; Brabbins DS; Chen PY; Floyd W; Martinez AA
    Gynecol Oncol; 2006 Oct; 103(1):87-93. PubMed ID: 16545441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study.
    Kurnit KC; Nobre SP; Fellman BM; Iglesias DA; Lindemann K; Jhingran A; Eriksson AGZ; Ataseven B; Glaser GE; Mueller JJ; Westin SN; Soliman PT
    Gynecol Oncol; 2022 Dec; 167(3):452-457. PubMed ID: 36243601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy.
    Nelson G; Randall M; Sutton G; Moore D; Hurteau J; Look K
    Gynecol Oncol; 1999 Nov; 75(2):211-4. PubMed ID: 10525373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study.
    Mahdi H; Rose PG; Elshaikh MA; Munkarah A; Isrow D; Singh S; Waggoner S; Ali-Fehmi R; Morris RT; Harding J; DeBenardo R
    Gynecol Oncol; 2015 Mar; 136(3):529-33. PubMed ID: 25575483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-Dose Adjuvant Cylinder Brachytherapy for Endometrioid Endometrial Cancer.
    Alban GM; Buscariollo DL; Cheng T; Pretz J; Krechmer B; Buzurovic I; Singer L; King M; Lee L
    Pract Radiat Oncol; 2020; 10(2):95-103. PubMed ID: 31783169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
    de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; D'Amico R; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Gribaudo S; Provencher D; Hanzen C; Kruitwagen RF; Smit VTHBM; Singh N; Do V; Lissoni A; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
    Lancet Oncol; 2019 Sep; 20(9):1273-1285. PubMed ID: 31345626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer.
    Townamchai K; Berkowitz R; Bhagwat M; Damato AL; Friesen S; Lee LJ; Matulonis U; O'Farrell D; Viswanathan AN
    Gynecol Oncol; 2013 Apr; 129(1):18-21. PubMed ID: 23262378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do vaginal recurrence rates differ among adjuvant vaginal brachytherapy regimens in early-stage endometrial cancer?
    Ager BJ; Francis SR; Do OA; Huang YJ; Soisson AP; Dodson MK; Werner TL; Sause WT; Grant JD; Gaffney DK
    Brachytherapy; 2019; 18(4):453-461. PubMed ID: 31005603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravaginal high-dose-rate brachytherapy for Stage IB (FIGO Grade 1, 2) endometrial cancer.
    Alektiar KM; McKee A; Venkatraman E; McKee B; Zelefsky MJ; Mychalczak BR; Hoskins WJ; Barakat RR
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):707-13. PubMed ID: 12062616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.